Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland.

QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Quadralogic Technologies, Inc. is a Canadian private company located in Vancouver, BC, that manufactures pharmaceutical and herbicide products.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Operates a biomedical group

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

QLT PhotoTherapeutics, Inc., a subsidiary of Novelion Therapeutics, Inc., is a company headquartered in Vancouver, BC, Canada. The firm manufactures and develops drugs.

Janssen Diagnostics LLC, a subsidiary of Johnson & Johnson, is an American company located in Raritan, NJ. The firm designs and manufacture special machinery for the pharmaceutical industry.

Part of Nanjing Panda Electronics Co. Ltd., Nanjing Longwill Communications Technology Co. Ltd. is a company headquartered in Nanjing, China. The firm manufactures and distributes communications equipment. Nanjing Panda Electronics Co. Ltd. acquired Nanjing Longwill Communications Technology Co. Ltd. from Panda Electronics Group Co., Ltd. on November 17, 2011 for $0.48 million.

Panda Electronics Group Co., Ltd. is a state-owned electronics enterprise in China. Its business covers multiple industries including modern communications, digital audio/video and smart electronics system, electronics equipment and electronics manufacturing. The company was founded in 1936 and is headquartered in Jiangsu, CN.

Nanjing Dongda Mobile Internet Technology Co., Ltd., established on 2002-01-15, Business scope includes communication technology(soft,the hardware)Research,to develop,Production,Sales and technical consultation,Technology transfer;Sales of instrument products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

SyntheX created a novel cell-based, synthetic biology-driven drug selection platform, that allows for the efficient synthesis and identification of peptides and macrocycles that selectively disrupt intracellular protein-protein interactions of interest. Although the platform has broad application, the initial focus is on oncology. Targets are selected based on the concepts of synthetic lethality and oncogene addiction, with the first program focused on DNA damage repair and working through a novel cell death mechanism that was uncovered.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

Zhikang International Life and Health Management Co., Ltd., established on 2018-05-25, Business scope includes medical research and experimental development;the first sort,R&D of Class II Medical Devices,Production,Sales;Technology development in the field of biology,Technology Promotion,technology transfer,technical consulting,Technical Services;property management;health management,Health Consulting Services(The above two items do not include items subject to permit approval);culture,Art Event Planning;Enterprise Management Services(Items not subject to approval);Corporate Image Planning Service;trade information,Educational Information Consulting Services;design,make,acting,Publish various domestic advertisements;Conference and Exhibition Services;translation service;Pre-packaged food,bulk food,Healthy food,Cosmetic sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

KaiBioTech Co., Ltd. engages in developing and manufacturing radiopharmaceuticals, dementia agents, and liver therapeutics. The company was founded on December 18, 2012 and is headquartered in Jeonju-si, South Korea.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Shenzhen Homed Medical Device Co., Ltd. is a Chinese private company located in Shenzhen that manufactures and distributes medical devices.